BiotechTube

HRS -8427 + Imipenem and Cilastatin Sodium

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Conditions

Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Trial Timeline

Dec 1, 2023 → Jul 1, 2024

NCT ID
NCT06144060

About HRS -8427 + Imipenem and Cilastatin Sodium

HRS -8427 + Imipenem and Cilastatin Sodium is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP). The current trial status is unknown. This product is registered under clinical trial identifier NCT06144060. Target conditions include Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06144060Phase 2UNKNOWN

Competing Products

20 competing products in Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + Epoetin betaChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
FK949EAstellas PharmaPhase 1
33
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP7991Astellas PharmaPhase 1
33
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
ATG-FAstellas PharmaApproved
85
CelecoxibAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85